beta
/Lilly to acquire Scorpion Therapeutics' mutant-selective π³Kα inhibitor program
NEWS

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

PRNewswire
2025/01/13

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

(PRNewsfoto/Eli Lilly and Company)

Scorpion Therapeutics, Inc.

Summary

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule...